Females versus males | 0.013 | 0.81 |
Age | <0.0001 | 0.038 (0.09) |
History | | |
Birthweight | 0.018 (0.13) | 0.011 (0.14) |
Early wheezing | 0.36 | 0.028 |
Atopic dermatitis | 0.52 | 0.31 |
Parental smoking | 0.56 | 0.17 |
Atopic status | | |
Negative/positive SPT | 0.19 | 0.42 |
Treatment | | |
β-agonist on demand | 0.22 | 0.93 |
ICS dose in treated children | 0.60 | 0.30 |
LABA | 0.85 | 0.84 |
Symptoms | | |
Percentage of symptom-free days | 0.043 (0.09) | 0.84 |
Severe exacerbation | 0.90 | 0.34 |
Exercise complaints (3 levels) | 0.0001 | 0.024 |
Play team versus no symptom | 0.75 | 0.77 |
Long-distance race versus no symptom | <0.0001 | 0.006 |
Long-distance race versus play team | 0.007 | 0.17 |
Baseline spirometry | | |
FVC % pred | <0.0001 (0.19) | |
FVC z-score | | <0.0001 (0.20) |
FEV1 % pred | 0.27 | |
FEV1 z-score | | 0.014 (0.12) |
FEV1/FVC % | 0.0001 (-0.19) | |
FEV1/FVC % pred | 0.01 (-0.12) | |
FEV1/FVC z-score | | 0.019 (-0.11) |
FEF25–75% % pred | 0.36 | |
FEF25–75% z-score | | 0.78 |
Baseline plethysmography | | |
sRaw kPa·s−1 | 0.054 (-0.09) | 0.57 |
TLC % pred | 0.42 | 0.24 |
FRC % pred | 0.0001 (-0.17) | 0.001 (-0.15) |
FRC/TLC | 0.002 (-0.15) | <0.0001 (-0.24) |
RV % pred | <0.0001 (−0.23) | 0.002 (-0.15) |
RV/TLC | <0.0001 (-0.38) | <0.0001 (-0.23) |
BD response FEV1 | 0.93 | 0.83 |
BD response sRaw | 0.82 | 0.65 |
FeNO | 0.99 | 0.16 |